Skip to content

Familial Aortopathies and Cellular Exploration

ACTA2 and Familial Aortopathies: Creation and Validation of an Exploratory Cellular Model

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05401500
Acronym
FACE
Enrollment
3
Registered
2022-06-02
Start date
2022-06-01
Completion date
2023-06-01
Last updated
2022-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial Aortopathies

Brief summary

The prevalence of hereditary aortic disease (HTAD), responsible for aneurysm or dissection, is estimated at 25%. Mutations in the ACTA2 gene represent the main cause of non-syndromic forms (10-21%). ACTA2 is expressed in vascular wall smooth muscle cells (VSMC) and encodes alpha actin (α-SMA). This actin isoform is in the majority in VSMCs and plays a key role in their contractile properties. The mutations are dominant-negative and lead, in a fibroblast model, to defects in the organisation of the actin cytoskeleton and to an increase in the migratory and proliferative potential of the cells. In vivo, VSCMs exist in a phenotypic continuum ranging from a quiescent differentiated contractile state to a so-called synthetic state in which cells are proliferative, synthesise extracellular matrix elements and exhibit enhanced migratory capabilities. To understand how ACTA2 mutations deregulate VSMC functions and steer them towards a synthetic phenotype, it is necessary to have a cellular model as close as possible to the affected tissue..

Interventions

BIOLOGICALblood sample

blood sampling

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patient with a mutation in the ACTA2 gene

Exclusion criteria

* patient under 18 years of age at the time of inclusion

Design outcomes

Primary

MeasureTime frameDescription
analysis of the impact of ACTA2 mutations on the morphology of the actin cytoskeletonbaselineuse of a model of IPS cells reprogrammed into VSMCs from patients with ACTA2 mutations, compared to a healthy control

Countries

France

Contacts

Primary ContactLaurence Bal, MD
laurence.bal@ap-hm.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026